Summit Therapeutics Inc [SMMT] stock is trading at $18.61, down -1.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on September 27, 2024, when Citigroup downgraded its rating to a Neutral and also boosted its price target to $23 from $19. Previously, H.C. Wainwright started tracking the stock with Buy rating on August 12, 2024, and set its price target to $16. On May 07, 2024, Citigroup initiated with a Buy rating and assigned a price target of $7 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $8 on March 26, 2024. Janney downgraded its rating to a Neutral. In a note dated April 12, 2018, Needham reiterated an Buy rating on this stock and revised its target price from $30 to $27.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $1.64 and $33.89 over the past year. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $18.61 at the most recent close of the market. An investor can expect a potential return of 93.44% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
Gross Profit Margin for this corporation currently stands at 6.32% with Operating Profit Margin at 523.84%, Pretax Profit Margin comes in at 688.73%, and Net Profit Margin reading is 688.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -1.55 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.33 points at the first support level, and at 18.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.01, and for the 2nd resistance point, it is at 19.41.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 2.35. In addition, the Quick Ratio stands at 2.35 and the Cash Ratio stands at 0.21.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
